Villejuif

• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi … Recruiting
  2023-509334-19-00 5 2024-10-17 gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• First-in-human Trial of EGL-001 in Patients with Selected Advanced and/or Metastatic Solid Tumors Recruiting
  2024-512921-10-00 1 2024-09-27 Advanced and/or Metastatic Solid Tumors
• tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting
  2023-503316-33-00 5 2024-09-26 patients with a positive status for molecular residual disease (MRD) [
• A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu … Recruiting
  2023-510203-21-00 7 2024-09-24 locally advanced or metastatic non-small cell lung cancer (NSCLC) resi
• A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl … Recruiting
  2022-500800-24-00 4 2024-09-19 Multiple Myeloma
• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting
  2024-515118-42-00 11 2024-09-10 Colorectal cancer
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting
  2023-504013-68-00 1 2024-09-06 Advanced or Metastatic Prostate Cancer
• A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors Recruiting
  2023-504139-42-00 7 2024-09-06 Advanced or metastatic solid tumors
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tum … Recruiting
  2022-502757-34-00 1 2024-08-20 Advanced solid tumors
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting
  2023-508435-31-00 1 2024-08-09 Advanced Solid Tumors, Advanced Breast Cancer
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 4 2024-07-18 Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting
  2023-504910-31-00 5 2024-07-15 Non-small Cell Lung Cancer (NSCLC)
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting
  2022-500013-32-01 5 2024-07-05 Adrenocortical carcinoma
• Pan-lesions SBRT combined with lymphocyte support through ATRA-driven blockade of MDSC in patients with oligometastatic solid cancer (LySATR … Recruiting
  2022-500680-13-00 9 2024-07-04 Oligometastatic solid cancer

Showing 337–360 of 961 trials